在线国产一区二区_成人黄色片在线观看_国产成人免费_日韩精品免费在线视频_亚洲精品美女久久_欧美一级免费在线观看

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Technology

China's domestic biotech industry is becoming a global force

By Li Jing | chinadaily.com.cn | Updated: 2025-07-16 21:33
Share
Share - WeChat

China's domestic biotech industry is entering a new phase of international influence, as homegrown innovative drugs increasingly meet global clinical demand. One recent example is Dizal Pharma, a Wuxi-based biotech firm that has emerged as a model for China's evolving pharmaceutical ambitions.

On July 10, Dizal's lung cancer drug, sunvozertinib, was officially included in the US National Comprehensive Cancer Network treatment guidelines. The recognition followed approval from the US Food and Drug Administration a week earlier, making it the first-ever China-originated innovative medicine approved for EGFR exon20ins-mutated lung cancer in the US.

Sunvozertinib targets a rare but difficult-to-treat form of non-small cell lung cancer caused by EGFR exon20ins mutations. While these mutations only occur in about 2 to 4 percent of NSCLC cases, the sheer number of lung cancer patients worldwide makes that percentage substantial.

This subset of patients has few safe and effective options. The mutation itself is heterogeneous, with more than 130 different mutant subtypes. Most existing therapies don't work.

According to Dizal founder and CEO Zhang Xiaolin, what sets Dizal apart is its "original innovation". Rather than modifying an existing drug, Dizal's scientists designed an entirely new molecule from scratch. A 2022 study in Cancer Discovery underscored this breakthrough, showing that sunvozertinib's efficacy stems from its uniquely flexible chemical scaffold, tailored to tackle mutation diversity head-on.

"From the very beginning, we didn't outsource critical trials," Zhang said.

"We believed in building an in-house, globally capable team—culturally attuned, scientifically rigorous, and willing to face failure."

This team led sunvozertinib through rigorous international multi-center clinical trials—including collaborations with Harvard-affiliated hospitals—offering early-phase data across both Asian and non-Asian populations, a key requirement for FDA acceptance.

"Sunvozertinib is not just a scientific breakthrough—it's proof that China's homegrown innovation can meet global standards," said Zhang.

The achievement comes amid a wave of supportive national policies over the past two years. On July 1, the National Healthcare Security Administration and the National Health Commission jointly announced a series of measures to encourage novel drug development, including the creation of a commercial insurance catalog for innovative medicines that patients could be reimbursed for. Recent reforms to capital markets—such establishing a new segment on the tech-heavy STAR Market to host pre-profit companies—are also helping accelerate the sector's growth.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 国产视频一区在线 | 久久九九国产精品 | 成人超碰| 日本精品久久久久久久 | 久久久久91 | 欧美日韩啪啪 | 秋霞国产| 日韩第1页 | 日韩精品在线网站 | 日韩欧美中文字幕在线视频 | 国产精品久久久久久久久久久久久 | 日本一区二区三区四区视频 | 欧美精品一二三区 | 黄色在线免费看 | 亚洲蜜臀av乱码久久精品蜜桃 | 黄网在线 | 欧美成人精品一区 | 亚洲一区二区高清视频 | 91精品国产综合久久久久久 | 国产成人精品久久 | 国产乱码精品一区二区三区爽爽爽 | 电影一区二区在线 | 欧美一区2区三区4区公司二百 | 一级免费毛片 | 伊人免费在线观看高清版 | 天天曰 | 国色天香成人网 | 色伊人网| 成人免费观看在线视频 | 国产精品久久二区 | 一级片免费观看 | 午夜影院在线 | 国产乱码精品一品二品 | 久久亚洲精品中文字幕 | 亚洲黄色性视频 | 日本成人一区 | 亚洲精品亚洲人成人网 | 国产福利一区二区三区在线观看 | 日韩中文字幕在线视频 | 国产传媒毛片精品视频第一次 | 久久精品国产99 |